TABLE 5.

Incidence of adverse events occurring in each cohort

AEa	No. (%) of subjects with AE
	eGFR				ESRD (n = 8)
	Normal (n = 7)	Mild (n = 8)	Moderate (n = 8)	Severe (n = 8)
Any treatment emergent AE	1 (14.3)	0	0	2 (25.0)	1 (12.5)
Any treatment-related AE	0	0	0	1 (12.5)	0
Abdominal pain	0	0	0	1 (12.5)	0
Arteriovenous fistula	0	0	0	0	1 (12.5)
COVID-19	1 (14.3)	0	0	0	0
Diarrhea	0	0	0	1 (12.5)	0
Presyncope	0	0	0	1 (12.5)	0

^aAE, adverse event.